Neumora Therapeutics (NMRA) announced results from the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive disorder. The KOASTAL-1 Study is the first of three replicate ...
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that ...
Medpage Today on MSN1d
6% of Seniors Depressed; ADHD and Hormones; Novel Antipsychotic Eases SchizophreniaA study of older adults showed that 6% had depression, with higher prevalences in certain groups, including women, those who ...
The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...
Hosted on MSN1h
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & MoreIt was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on ...
Neumora Therapeutics’ phase 3 KOASTAL-1 study of navacaprant in MDD fails to meet primary endpoint
Watertown, Massachusetts Friday, January 3, 2025, 18:00 Hrs [IST] ...
Navacaprant failed to meet both primary and secondary endpoints in the study, which led to Neumora's stock plummeting approximately 80%, a stark contrast to the 2% gain in the XBI biotech index.
On Friday, Mizuho (NYSE:MFG) Securities reiterated its Outperform rating on Neumora Therapeutics (NASDAQ:NMRA) with a steady price target of $20.00, despite the company's recent setback with its lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback